Erasca Yönetim
Yönetim kriter kontrolleri 3/4
Erasca's CEO is Jonathan Lim, appointed in Jul 2018, has a tenure of 6.33 years. total yearly compensation is $5.41M, comprised of 11.5% salary and 88.5% bonuses, including company stock and options. directly owns 11.46% of the company’s shares, worth $88.01M. The average tenure of the management team and the board of directors is 3.5 years and 6.1 years respectively.
Anahtar bilgiler
Jonathan Lim
İcra Kurulu Başkanı
US$5.4m
Toplam tazminat
CEO maaş yüzdesi | 11.5% |
CEO görev süresi | 6.3yrs |
CEO sahipliği | 11.5% |
Yönetim ortalama görev süresi | 3.5yrs |
Yönetim Kurulu ortalama görev süresi | 6.1yrs |
Son yönetim güncellemeleri
Recent updates
We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth
Oct 15Erasca: New Focus After Restructuring, But Need More Differentiation
Sep 30Is Erasca (NASDAQ:ERAS) In A Good Position To Deliver On Growth Plans?
Feb 21We Think Erasca (NASDAQ:ERAS) Needs To Drive Business Growth Carefully
Nov 16Companies Like Erasca (NASDAQ:ERAS) Are In A Position To Invest In Growth
Jun 28We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth
Jan 20Erasca forms clinical trial partnership with Pfizer for cancer therapy
Oct 20Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation
Sep 23Erasca adds 10% ahead of R&D Day
Sep 07Erasca, Eli Lilly to collaborate on trial to evaluate combo treatment for two cancers
Jul 18We're Not Very Worried About Erasca's (NASDAQ:ERAS) Cash Burn Rate
Apr 12Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation
Dec 28CEO Tazminat Analizi
Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$158m |
Mar 31 2024 | n/a | n/a | -US$127m |
Dec 31 2023 | US$5m | US$623k | -US$125m |
Sep 30 2023 | n/a | n/a | -US$231m |
Jun 30 2023 | n/a | n/a | -US$236m |
Mar 31 2023 | n/a | n/a | -US$240m |
Dec 31 2022 | US$8m | US$593k | -US$243m |
Sep 30 2022 | n/a | n/a | -US$138m |
Jun 30 2022 | n/a | n/a | -US$149m |
Mar 31 2022 | n/a | n/a | -US$141m |
Dec 31 2021 | US$850k | US$498k | -US$123m |
Sep 30 2021 | n/a | n/a | -US$154m |
Jun 30 2021 | n/a | n/a | -US$119m |
Mar 31 2021 | n/a | n/a | -US$96m |
Dec 31 2020 | US$2m | US$300k | -US$102m |
Tazminat ve Piyasa: Jonathan's total compensation ($USD5.41M) is above average for companies of similar size in the US market ($USD3.24M).
Tazminat ve Kazançlar: Jonathan's compensation has been consistent with company performance over the past year.
CEO
Jonathan Lim (52 yo)
6.3yrs
Görev süresi
US$5,407,446
Tazminat
Dr. Jonathan E. Lim, M.D., Co-founded Erasca, Inc. in July 2018 and has been its Executive Chairman since October 2018 and Chief Executive Officer since March 2019. Dr. Lim has also served as a Venture Par...
Liderlik Ekibi
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
Co-Founder | 6.3yrs | US$5.41m | 11.46% $ 88.0m | |
CFO & Chief Business Officer | 3.9yrs | US$2.43m | 0.087% $ 671.1k | |
General Counsel & Corporate Secretary | 3.6yrs | US$2.02m | 0.0034% $ 26.4k | |
Chairman of Research & Development | 4.3yrs | US$199.05k | 0% $ 0 | |
Chief Operating Officer | 3.5yrs | Veri yok | Veri yok | |
Chief People Officer | 2.8yrs | Veri yok | Veri yok | |
Senior Vice President of Finance | 3.5yrs | Veri yok | Veri yok | |
Chief Regulatory Affairs Officer | 3.5yrs | Veri yok | Veri yok | |
Senior Vice President of Research | 3yrs | Veri yok | Veri yok | |
Chief Medical Officer | 2.5yrs | Veri yok | Veri yok | |
Senior Vice President of Pharmaceutical Development & Operations | 2yrs | Veri yok | Veri yok | |
Senior Vice President of Clinical Pharmacology | 1.5yrs | Veri yok | Veri yok |
3.5yrs
Ortalama Görev Süresi
52.5yo
Ortalama Yaş
Deneyimli Yönetim: ERAS's management team is considered experienced (3.5 years average tenure).
Yönetim Kurulu Üyeleri
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
Co-Founder | 6.1yrs | US$5.41m | 11.46% $ 88.0m | |
Chairman of Research & Development | 4.3yrs | US$199.05k | 0% $ 0 | |
Scientific Advisory Board Member | no data | Veri yok | Veri yok | |
Independent Director | 6.3yrs | US$167.54k | 0.24% $ 1.8m | |
Independent Director | 6.3yrs | US$156.54k | 0.061% $ 470.2k | |
Scientific Advisory Board Member | no data | Veri yok | Veri yok | |
Independent Director | 6.4yrs | US$180.08k | 0.073% $ 564.4k | |
Independent Director | 3.7yrs | US$165.04k | 0.0021% $ 16.3k | |
Scientific Advisory Board Member | no data | Veri yok | Veri yok | |
Independent Director | 5.4yrs | US$165.54k | 0.0078% $ 59.8k | |
Scientific Advisory Board Member | no data | Veri yok | Veri yok | |
Scientific Advisory Board Member | no data | Veri yok | Veri yok |
6.1yrs
Ortalama Görev Süresi
65yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: ERAS's board of directors are considered experienced (6.1 years average tenure).